Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note released on Friday morning, Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

Immix Biopharma Price Performance

Shares of NASDAQ:IMMX opened at $2.24 on Friday. Immix Biopharma has a 1 year low of $1.55 and a 1 year high of $7.75. The business’s 50-day moving average is $2.13 and its 200-day moving average is $2.84.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Equities analysts anticipate that Immix Biopharma will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Imprint Wealth LLC raised its holdings in shares of Immix Biopharma by 49.4% during the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock valued at $239,000 after purchasing an additional 11,400 shares during the period. OLD National Bancorp IN bought a new position in Immix Biopharma in the fourth quarter worth approximately $69,000. Private Advisor Group LLC bought a new position in Immix Biopharma in the fourth quarter worth approximately $690,000. Jump Financial LLC acquired a new stake in Immix Biopharma in the fourth quarter valued at approximately $128,000. Finally, Tritonpoint Wealth LLC bought a new stake in shares of Immix Biopharma during the first quarter valued at approximately $75,000. 11.26% of the stock is owned by institutional investors.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.